Lino Biotech
Acquisition in 2023
Lino Biotech AG is a biotechnology company based in Zurich, Switzerland, founded in 2020. It specializes in developing a unique biosensor platform based on Focal Molography, an innovative method for measuring biomolecular interactions in living cells and crude biological samples. This technology enables label-free detection assays that are resistant to signal disturbances from temperature fluctuations and non-specific binding. Lino Biotech's platform aims to enhance the quality control processes for cell therapy manufacturers, making cell therapies more cost-effective and accessible to a wider patient population. By providing advanced measurement capabilities, the company supports improvements in the production and development processes of cell therapies.
Sensovation AG
Acquisition in 2017
Sensovation AG engages designs, develops, manufactures, and distributes camera based sensors and electro optical measurement systems for biotechnology, medical technology, and diagnostics applications. It offers cameras, such as SamBa Ci that is used for the inspection of solar cells; coolSamBa HR-830 that is used for the electroluminescence inspection of modules in photovoltaic industries.
Lentigen
Acquisition in 2014
Lentigen Corporation, a biotechnology company, engages in the development and commercialization of gene delivery technologies for human disease. It provides lentiviral vector technology for a range of therapeutic, vaccine, and research applications in biotechnology and medicine. The company offers LG690, a cell therapy for treatment of graft vs hot diseases; LG768, a cancer vaccine for the treatment of leukemia; stem cell therapy to prevent and treat medical disorders; LG631, a treatment that makes chemotheraphy for brain cancer less toxic; LG889, a steam cell therapy for hemophilia; LG611, an exact strain matched influenza vaccine for pandemic flu; LG811, an exact strain matched influenza vaccine for seasonal flu; LG747, a biosimilar erytho poieitin; and LG888, a novel factor VIII protein therapy for Hemophilia A. Lentigen Corporation was founded in 2004 and is headquartered in Gaithersburg, Maryland.
OWL Biomedical
Acquisition in 2013
Owl Biomedical, Inc. is a biotechnology company based in Santa Barbara, California, that specializes in developing microchip-based disposable cell sorting technology. Founded in 2010, the company focuses on applications in cell purification, cancer diagnostics, and regenerative medicine, including adoptive immunotherapy and stem cell therapies. Owl Biomedical's innovative technology is utilized in both basic research and clinical settings, facilitating advancements in stem cell and cancer research, as well as applications in the cosmetic and aesthetic markets. In 2013, the company became a subsidiary of Miltenyi Biotec GmbH, further enhancing its capabilities and market reach.
Eligix
Acquisition in 2003
Eligix, Inc., a biomedical company, engages in the research and development of cellular therapies. The therapies improve human immune response to cancers, autoimmune disorders, and solid organ transplants; and reduce the risk of infection and hypersensitivity reactions in blood transfusions.